February 21, 2023

Rudy Tanzi and the Latest Alzheimer’s Drugs - part 1

Rudy Tanzi and the Latest Alzheimer’s Drugs - part 1

About This Episode

Will 2023 be a boom or bust year for new Alzheimer’s drugs? 

In this episode of BrainStorm host Meryl Comer talks with Dr. Rudy Tanzi, Vice-Chair of Neurology at Massachusetts General Hospital, Co-Director of the McCance Center for Brain Health and Professor at Harvard Medical School.  Dr. Tanzi discusses the promising new drugs in a highly charged scientific environment and how these drugs have opened the door to advancement in the treatment of Alzheimer’s. 

Support the show

BrainStorm Feed

100

2025 Year in Review and Predictions for 2026 with George Vradenburg

George Vradenburg, Chairman and Founder of UsAgainstAlzheimer's, sits down with host Meryl Comer for a comprehensive look at the state of Alzheimer's research, advocacy, and care in 2025.
LISTEN NOW
99

The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

In part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials.
LISTEN NOW
98

The Future of Alzheimer's Trials: Bringing Cutting-Edge Research to Every Community - John Dwyer, CEO of The Global Alzheimer's Platform

John Dwyer, CEO of the Global Alzheimer's Platform (GAP), highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities.
LISTEN NOW